$3 Bn Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2019-2024

Dublin, Feb. 13, 2019 (GLOBE NEWSWIRE) -- The "Premature Ejaculation Therapeutics Market - Global Outlook and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.



The global premature ejaculation therapeutics market is estimated to reach revenues of approximately $3 billion by 2024, growing at a CAGR of around 9% during 2018-2024.



The entry of new vendors is leading to high capital investment for R&D activities and manufacturing of new prescription drugs in the global market. The increasing awareness and focus on sexual wellness will create lucrative opportunities for leading vendors operating in the market.



The global premature ejaculation therapeutics market is driven by growing patient willingness to seek pharmaceutical therapy assistance for disease management. The launch of off-label drugs belonging to SSRIs and topical formulations will revolutionize the global market over the next few years. The market research report provides in-depth market analysis and segmental analysis of the global premature ejaculation therapeutics market by drug class, ROA, and geography.



Premature Ejaculation Therapeutics Market - Dynamics



PE is one of the common sexual disorders prevalent in men. Many results from many epidemiological studies, PE is considered to be the most prevalent sexual disorder in men. Globally, the prevalence rate of PE is in the range of 25% to 40% in men across all age groups. As per estimates, the prevalence of PE is more than 20% in regions like Europe, APAC, Latin America, and North America. The Middle East and African regions have a prevalence rate of 13% and 11% respectively.



The existence of non-pharmacological treatment modalities, multiple international and regional guidelines recommend the administration of pharmacological agents (alone or in a combination of behavioral techniques/psychological therapy and drug therapy) as the first-line option for the management of the lifelong or acquired PE. The prime factor in the recommendation of drug therapy is its superiority than other non-pharmacological therapies.



In addition, many research studies confirmed that therapeutic intervention with various available drugs is effective in improving the signs and symptoms of PE. Pharmaceutical advances are continually leading to the innovation of new drug formulations and drug delivery systems. These advances are improving the efficacy and safety of drugs by enhancing bioavailability, improving drug absorption and modifying the rate of drug release.



Premature Ejaculation Therapeutics Market - Segmentation



This market research report includes a detailed segmentation of the market by drug class, ROA, and geography. The global premature ejaculation therapeutics market by drug class is segmented into SSRIs, PDE5 inhibitors, anesthetic agents, and others. SSRIs segment dominated more than 1/3rd of the total market share in 2018, growing at a CAGR of more than 8% during the forecast period. SSRIs is the most common type of drug for premature ejaculation treatment, and the introduction of Priligy (dapoxetine), which gained regulatory approval in 2009 is fueling the growth of this segment in the global market. Some of the common brand names of PDE5 inhibitors that are available in the global market include Cialis, Viagra, and Levitra. The plethora of unlicensed formulations, comprising anesthetic drugs and anesthetic agents will lead to an increase in clinical trials in the market.



The ROA segment in the global premature ejaculation therapeutics market is classified into oral therapeutics and topical therapeutics. Topical therapeutics is the fastest growing segment in the global market, at a CAGR of over 10% during the forecast period. The continual approval for new topical OTC formulations, rise in product uptake of existing products due to increase in disease awareness, and interest of couples for sexual wellbeing are some of the factors attributing to the growth of this segment in the global market. The daily dose oral therapies can exhibit improved and enhanced efficacy over topical therapies for treating PE. Some of the leading off-label oral formulation brands available in the global premature ejaculation therapeutics market are Viagra, Cialis, Zoloft, Paxil, Prozac, Levitra, and Lexapro.



Key Vendor Analysis



The global premature ejaculation therapeutics market is fairly fragmented due to the presence of pharma companies and generic manufacturers. The top vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents to attract the maximum number of consumers in the global market. The exponential growth of the APAC and Latin American region will create lucrative investment opportunities for prominent players in the market. Factors such as access to drugs, high disease awareness, and high affordability will help companies boost revenues in the global premature ejaculation therapeutics market.



The major vendors in the global market are:

• Absorption Pharmaceuticals
• Innovus Pharmaceuticals
• Pfizer
• Plethora Solutions Holdings

Key Topics Covered:



1 Research Methodology



2 Research Objectives



3 Research Process



4 Report Coverage

4.1 Market Definition

4.2 Base Year

4.3 Scope of Study



5 Report Assumptions & Caveats

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation



6 Market at a Glance



7 Introduction

7.1 Premature Ejaculation: An Overview

7.1.1 Premature Ejaculation Definition

7.1.2 Disease Overview

7.1.3 Classification of Premature Ejaculation

7.1.4 Symptoms of PE

7.1.5 Aetiology of Premature Ejaculation

7.1.6 Epidemiology



8 ISSN Guidelines on Premature Ejaculation

8.1 Disease Assessment

8.1.1 Patient History

8.1.2 Physical Examination

8.1.3 Assessment Instruments

8.2 Treatment Options for PE

8.2.1 Physiological Therapy

8.2.2 Behavioral Techniques

8.2.3 Pharmacological Treatment



9 Clinical Trial Landscape

9.1 Overview

9.1.1 Subjects Selection Criteria for PE Clinical Trials

9.1.2 Clinical Trial Data Evaluation Considerations

9.1.3 Clinical Trial Design Considerations for PE

9.2 Clinical Trial EndPoints



10 Pipeline Landscape

10.1 Overview

10.2 Key Pipeline Drug Candidates

10.3 Key Pipeline Molecules

10.3.1 Epelsiban

10.3.2 IX-01

10.3.3 DA-8031

10.4 Dormant/Terminated/Withdrawn Drug Candidates



11 Market Dynamics

11.1 Market Growth Enablers

11.1.1 Increase in the Prevalence of PE and Other Chronic Diseases in Men

11.1.2 Wide Accessibility to PE OTC Drugs and Generic Off-label Drugs

11.1.3 Low-effectiveness of Non-pharmacological PE Treatment

11.1.4 Presence of High Unmet Demand

11.2 Market Growth Restraints

11.2.1 Low Treatment Seeking Patient Pool

11.2.2 Presence of Alternative PF Treatment Methods

11.2.3 Clinical Trial Withdrawals/Terminations and Inactive Clinical Studies

11.2.4 Associated Adverse Effects of PE Drugs

11.3 Market Opportunities & Trends

11.3.1 Advances in PE Drug Formulation Technology

11.3.2 Emphasis on Clinical Progress of Love Hormone Receptor Antagonists

11.3.3 Increased Awareness Campaigns and Initiatives for PE Treatment



12 Global Premature Ejaculation Market

12.1 Market Overview

12.2 Market Size & Forecast

12.3 Porter's Five Forces Analysis



13 By Drug Class

13.1 Market Overview

13.2 SSRIs

13.3 PDE5 Inhibitors

13.4 Anesthetic Agents

13.5 Others



14 By Route of Administration

14.1 Market Overview

14.2 Oral Therapeutics

14.3 Topical Therapeutics



15 By Geography



Key Company Profiles

• Absorption Pharmaceuticals
• Innovus Pharmaceuticals
• Pfizer
• Plethora Solutions Holdings

Other Prominent Vendors

• Bayer
• Eli Lilly and Company
• GlaxoSmithKline
• Recordati
• Royalty Pharma
• The Menarini Group
• Ixchelsis
• NeuroHealing Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/research/kzmg2f/3_bn_premature?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Sexual and Reproductive Health Drugs